ARCELLX INC's ticker is and the CUSIP is 03940C100. A total of 120 filers reported holding ARCELLX INC in Q1 2023. The put-call ratio across all filers is 1.54 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $12,954,638 | -48.7% | 234,728 | -35.4% | 0.05% | -47.8% |
| Q1 2024 | $25,253,118 | +93.0% | 363,093 | +54.0% | 0.09% | +76.9% |
| Q4 2023 | $13,084,680 | +253.9% | 235,760 | +128.8% | 0.05% | +188.9% |
| Q3 2023 | $3,697,470 | -57.4% | 103,051 | -62.5% | 0.02% | -56.1% |
| Q2 2023 | $8,681,935 | +81.6% | 274,571 | +77.0% | 0.04% | +70.8% |
| Q1 2023 | $4,780,264 | +53.3% | 155,153 | +54.1% | 0.02% | +41.2% |
| Q4 2022 | $3,119,004 | – | 100,678 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SR ONE CAPITAL MANAGEMENT, LP | 5,500,007 | $170,390,217 | 62.20% |
| PATHWAY CAPITAL MANAGEMENT, LP | 189,120 | $5,858,938 | 10.46% |
| NEA Management Company, LLC | 4,745,262 | $147,008,217 | 8.26% |
| Samsara BioCapital, LLC | 957,451 | $29,661,832 | 6.38% |
| Soleus Capital Management, L.P. | 1,102,447 | $34,153,808 | 4.90% |
| Cormorant Asset Management, LP | 2,075,000 | $64,284 | 4.30% |
| Paradigm Biocapital Advisors LP | 882,101 | $27,327,489 | 3.21% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 2,350,333 | $72,813,316 | 3.06% |
| Affinity Asset Advisors, LLC | 240,143 | $7,439,630 | 2.92% |
| CAXTON CORP | 36,302 | $1,124,640 | 2.87% |